MorphoSys, partner of I-Mab, announces new licensing agreements for Felzartamab and TJ210

0

SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of novel biologics, today announced two assets including Company licensed from partner MorphoSys AG (FSE: MOR; NASDAQ: MOR), felzartamab (also known as TJ202/MOR202) and TJ210 (also known as MOR210), are progressing to scale through new licensing agreements.

MorphoSys and Human Immunology Biosciences, Inc. (HIBio), a biotechnology company focused on the development of precision drugs for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital, announced that the companies have entered into a equity investment agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, a CD38 antibody, and TJ210, a C5aR1 antibody, outside of Greater China. Currently, I-Mab is developing and commercializing felzartamab in Greater China and TJ210 in Greater China and South Korea.

Under the terms of the new agreements, HIBio will obtain exclusive development and commercialization rights to felzartamab and TJ210 in all indications worldwide, excluding Greater China for felzartamab and Greater China and South Korea for TJ210.

“We have made significant progress in developing felzartamab for registration in China and we brought TJ210 to the clinic from United States. We are delighted and look forward to working with MorphoSys and HIBio to advance the clinical development and commercialization of felzartamab and TJ210,” said Dr. Andrew Zhu, President of I-Mab. “This takes us one step further in delivering these innovative investigational drugs to China and other countries as soon as possible to benefit more patients. »

Based on a license agreement between MorphoSys and I-Mab signed in November 2017I-Mab has exclusive development and commercialization rights to felzartamab in Greater China. MorphoSys and I-Mab have entered into a strategic collaboration and exclusive license agreement to develop and commercialize the TJ210 in November 2018. Under the terms of the agreement, I-Mab has obtained exclusive development and commercialization rights to the TJ210 in Greater China and South Korea and share certain rights when I-Mab reaches previously agreed upon clinical milestones in the United States Through the productive partnership with MorphoSys, I-Mab has completed the registrational trial of felzartamab for third-line and advanced multiple myeloma (MM) the phase 3 trial for the second line MM in China. I-Mab is currently conducting a Phase 1 clinical trial in the United States for TJ210 in oncology indications.

About felzartamab

Felzartamab (TJ202/MOR202) is an investigational human monoclonal antibody derived from MorphoSys’ HuCAL® antibody technology. The antibody is directed against CD38 on the surface of multiple myeloma cells, which has been characterized as one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells. According to its suggested mode of action, the antibody recruits cells of the body’s immune system to kill the tumor through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The antibody does not involve complement-dependent cytotoxicity, or CDC, an additional immune mechanism involved in the destruction of tumor cells. Scientific research suggests that an anti-CD38 antibody may also have therapeutic potential in other cancers as well as autoimmune diseases. Based on a license agreement between MorphoSys and I-Mab signed in November 2017I-Mab has exclusive development and commercialization rights to TJ202/MOR202 on the continent China, Taiwan, hong kong and Macau.

HuCAL® is a registered trademark of MorphoSys AG.

About TJ210/MOR210

TJ210/MOR210 is a novel human antibody against C5aR1 derived from MorphoSys’ HuCAL Platinum® technology. C5aR1, the complement factor C5a receptor, is being investigated as a potential new drug target in the field of immuno-oncology and autoimmune diseases. Tumors have been shown to produce large amounts of C5a, which, by recruiting and activating myeloid suppressor cells (MDSCs), M2 macrophages and neutrophils, is thought to contribute to an immunosuppressive pro-tumorigenic microenvironment. TJ210/MOR210 is intended to block the interaction between C5a and its receptor, thereby potentially neutralizing the immunosuppressive function of C5a and allowing immune cells to attack the tumor.

HuCAL Platinum® is a registered trademark of MorphoSys AG.

About I-Mab

I-Mab (Nasdaq: IMAB) is a global, innovation-driven biopharmaceutical company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology diseases. The company’s mission is to bring transformational medicines to patients around the world through innovation. I-Mab’s globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its in-house discovery and global out-licensing partnerships, based on Fast processes. -to-Proof-of-Concept and Fast-to-Market development strategies. The company is evolving from a clinical-stage biotechnology company to an innovative global biopharmaceutical company with state-of-the-art R&D capabilities, a world-class GMP manufacturing facility and commercial capability. I-Mab established its global footprint in Shanghai (Headquarter), beijing, Hangzhou, CantonLishui and hong kong in Chinaand Maryland and San Diego in the USA. For more information, visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitterand WeChat.

I-Mab Forward-Looking Statements

This press release contains forward-looking statements. These statements are made pursuant to the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by words such as “will”, “expect”, “anticipate” , “future”, “intends”, “plans”, “believes”, “estimates”, “confidently”, and similar statements. Among other things, the business outlook and citations contained in this press release, as well as statements regarding felzartamab (TJ202/MOR202) and TJ210/MOR210 clinical trial data, potential implications of the clinical data for patients and the progress of I-Mab’s anticipated clinical development, regulatory milestones and commercialization of felzartamab (TJ202/MOR202) and TJ210/MOR210, contain forward-looking statements. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (“SEC”), in its annual report to shareholders, in press releases and other written materials, and in oral statements. made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Actual results may differ materially from those indicated in the forward-looking statements due to various important factors, including, but not limited to, I-Mab’s ability to demonstrate the safety and efficacy of its candidates- medications ; the clinical results of its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by relevant regulatory authorities regarding the regulatory approval of I-Mab’s drug candidates; I-Mab’s ability to achieve commercial success for its drug candidates, if approved; I-Mab’s ability to obtain and maintain intellectual property protection for its technology and medicines; I-Mab’s reliance on third parties to carry out drug development, manufacturing and other services; I-Mab’s limited operating history and I-Mab’s ability to obtain additional funds for its operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company’s clinical development, business and other operations, as well as the risks described in more detail in the “Risk Factors” section of I-Mab’s latest annual report on Form 20-F, as well as discussions of potential risks, uncertainties and other important factors in I-Mab’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, events future or otherwise, except to the extent possible. be required by law.

For more information please contact:

Contacts I-Mab

Richard Yeh
CEO
[email protected]

Gigi Feng
Head of Communications
[email protected]

Investor requests

Piacente Group, Inc.
Emilie Wu
E-mail: [email protected]
Office line: +86 21 6039 8363

SOURCEI-Mab

Share.

Comments are closed.